Kidney Cancer Drugs Market 2028 By Therapeutic Class, Pharmacologic Class and Geography | The Insight Partners

Kidney Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Class (Targetted Therapy, Immunotherapy); Pharmacologic Class (Angiogenesis Inhibitors, MTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)) and Geography

Report Code: TIPRE00003834 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

MARKET OVERVIEW



The term ""kidney cancer"" refers to cancer that begins in the kidneys. Renal cell carcinoma is the most prevalent type of kidney cancer, which usually develops as a single tumour within the kidney. Transitional cell carcinoma, Wilms tumour (nephroblastoma), renal sarcoma, renal adenomas, oncocytoma, and other types of kidney cancers. Kidney cancer is among the common types of cancers and is more prevalent in people above age of 60. Various treatment approaches such as, chemotherapy, radiation, surgery are available to treat kidney cancer.

MARKET SCOPE



The "Global Kidney Cancer Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Kidney cancer drugs market with detailed market segmentation by therapeutics class and pharmacologic class. The report provides key statistics on the market status of the leading Kidney cancer drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



  •   Based on therapeutic class the market is segmented as, targeted therapy and immunotherapy.
  •   Based on pharmacologic class the market is segmented as, angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (IL-2).

MARKET DYNAMICS


Drivers:



  •   Increasing prevalence of kidney cancers and other forms of renal carcinomas.
  •   Growing geriatric population across the globe.
  •   Presence of various risk factors such as, obesity, smoking, unhealthy lifestyles, blood pressure issues are also expected to spur the market growth.
  •   Extensive research and development activities to develop robust therapies for management of kidney cancers.
  •   Rising awareness and screening activities of cancers.

Restraints:



  •   However, high cost of therapies, poor reimbursement policies and chances of side effects from treatment are expected to restrain market growth during the forecast period.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Kidney cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Kidney cancer drugs market in these regions.

IMPACT OF COVID-19 ON KIDNEY CANCER DRUGS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for kidney cancer drugs and therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for kidney cancer therapeutics and drugs According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS



The report covers key developments in the Kidney cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Kidney cancer drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Kidney cancer drugs in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Kidney cancer drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Pfizer Inc.
  •   Novartis AG
  •   Bayer AG
  •   Genentech, Inc
  •   Bristol-Myers Squibb Company
  •   Exelixis, Inc.
  •   Eisai Inc
  •   Active Biotech AB
  •   GlaxoSmithKline plc
  •   F. Hoffmann-La Roche Ltd
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The List of Companies

- Pfizer Inc.
- Novartis AG
- Bayer AG
- Genentech, Inc
- Bristol-Myers Squibb Company
- Exelixis, Inc.
- Eisai Inc
- Active Biotech AB
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Amgen
- Merck Sharp and Dohme Corp
- AstraZeneca
TIPRE00003834
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount